Based on the provided data and current market conditions, here's a comprehensive analysis for ABBV's price movement in the next trading week:
Technical Analysis:
The stock is currently showing bearish signals in the short term, with RSI at 40.07 indicating a neutral to slightly oversold condition. The stock closed at $171.56 on Friday, below its 20-day moving average of $176.62 and 200-day moving average of $177.12, suggesting downward pressure.
News Sentiment and Catalysts:
Price Prediction for Next Week:
Target Prices:
Based on technical indicators and news sentiment:
Trading Recommendation: SELL Rationale:
Best entry for short positions: Current price ($171.56) Target exit: $167.50 Stop loss: $175.00
The price of ABBV is predicted to go up 3.32%, based on the high correlation periods with PFSI. The similarity of these two price pattern on the periods is 90.65%.
ABBV
PFSI
Year
ABBV Price Forecast($)
Potential Return(%)
2025
181.340
0.070
2026
216.000
19.190
2027
230.000
26.920
2028
230.000
26.920
2029
240.000
33.260
2030
250.000
38.810
AbbVie supports a strong dividend yield, which should act as valuation support, as the cash flows to support the dividend look secure over the next several years.
AbbVie's strong entrenchment in the aesthetics business (gained through the Allergan acquisition) sets up very long product cycles for several key assets like Botox based on strong brand power and physician entrenchment.
AbbVie's next generation immunology drugs targeting the IL23 and JAK pathways should help mitigate the competitive threats facing Humira over the next five years.
Truist Securities
Price Target
$215 → $211
Upside
+18.66%
Piper Sandler
Price Target
$212 → $220
Upside
+26.09%
B of A Securities
Price Target
$191
Upside
+8.38%